GlassScriptPhysician profile
Nhung Thi Le
NPI 1720550221
$3,893.58
in general payments reported to CMS, 2019-2025
20 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,169 · 2022: $872 · 2023: $820 · 2024: $575 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,851.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,432.13 | 2021-2025 | Airsupra, Tezspire, Breztri |
| Lilly USA, LLC | $615.48 | 2021-2025 | Mounjaro, Zepbound |
| Renalytix Ai, INC. | $418.22 | 2023-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Viiv Healthcare Company | $370.70 | 2021-2022 | |
| Averitas Pharma INC. | $257.97 | 2023 | Qutenza |
| Abbvie INC. | $225.97 | 2021-2024 | |
| Novo Nordisk INC | $198.60 | 2021-2023 | Wegovy |
| Grt US Holding, INC. | $87.16 | 2022 | |
| Amgen INC. | $38.81 | 2021-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $35.77 | 2023-2025 | |
| Astellas Pharma US INC | $31.05 | 2021 | |
| Avanir Pharmaceuticals, INC. | $28.90 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $26.25 | 2021 | |
| Genentech USA, INC. | $23.61 | 2021 | |
| Daiichi Sankyo INC. | $22.59 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.21 | 2021 | |
| Amarin Pharma, INC. | $16.63 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.69 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.27 | 2021 | |
| Mylan Specialty L.P. | $14.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nhung Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.